{"hypothesis_title":"Stathmin-2 Splice Switching to Prevent Axonal Degeneration Across the ALS-FTD-AD Spectrum","synthesis_summary":"The STMN2 splice switching hypothesis presents a mechanistically compelling pathway linking TDP-43 proteinopathy to axonal degeneration via poison exon dysregulation. The therapeutic approach is highly tractable given established ASO platform technology, though causal primacy of STMN2 depletion remains debated given the breadth of TDP-43 splicing targets. Preclinical iPSC data support the mechanism, but translation to human neurodegeneration requires demonstration of sufficient target engagement and single-target adequacy.","scores":{"mechanistic_plausibility":8.5,"evidence_strength":6.5,"novelty":6.0,"feasibility":8.5,"therapeutic_potential":8.0,"druggability":9.0,"safety_profile":7.5,"competitive_landscape":6.5,"data_availability":6.0,"reproducibility":7.0},"composite_score":7.2,"key_strengths":["Targets a well-characterized downstream effector of TDP-43 proteinopathy present across ALS-FTD-AD spectrum","Splice-switching ASO platform is clinically validated (nusinersen precedent) with favorable PK-PD relationships","Robust preclinical rescue demonstrated in human iPSC-derived motor neurons","Exon-skipping approach is straightforward to implement with established chemistry","Addresses a fundamental microtubule regulatory mechanism critical for axonal maintenance"],"key_weaknesses":["TDP-43 regulates hundreds of splicing targets; STMN2 may be one of many effectors rather than the critical driver","Single-target intervention may prove insufficient given network-level dysregulation","Poison exon inclusion mechanism requires further validation in vivo in human tissue","Biomarker for target engagement and patient selection needs development","Optimal timing of intervention relative to disease progression unclear"],"top_predictions":["ASO-mediated exon 2a skipping will restore STMN2 protein to physiological levels in patient-derived neurons and mouse models","STATHMIN-2 restoration will rescue microtubule stability and axonal transport deficits in a TDP-43-dependent manner","Patients with TDP-43 pathology and detectable STMN2 splicing dysregulation (not yet aggregated) will show greatest therapeutic response"],"recommended_next_steps":["Conduct comprehensive spliceome analysis in patient iPSC-derived neurons and affected human tissue to map STMN2 dysregulation relative to other TDP-43 targets","Develop pharmacodynamic biomarkers for target engagement (e.g., exon 2a inclusion ratio in accessible cells) for patient stratification","Optimize ASO chemistry for CNS delivery and conduct dose-finding studies in non-human primates","Establish proof-of-mechanism in multiple patient-derived cellular models representing ALS, FTD, and AD with TDP-43 pathology","Design basket trial stratified by TDP-43 proteinopathy status and STMN2 splicing dysregulation"],"evidence_for":[{"claim":"TDP-43 binds STMN2 pre-mRNA at UG-rich motifs and promotes exon 2a exclusion via U1 snRNP interaction","pmid":"30643219"},{"claim":"TDP-43 mislocalization and loss-of-function leads to cryptic exon inclusion and STMN2 depletion","pmid":"31063862"},{"claim":"ASO-mediated exon 2a skipping restores stathmin-2 levels and rescues axonal phenotypes in iPSC-motor neurons","pmid":"31171664"},{"claim":"TDP-43 proteinopathy is observed across ALS-FTD-AD spectrum disorders","pmid":"29299922"}],"evidence_against":[{"claim":"TDP-43 regulates hundreds of splicing targets beyond STMN2, questioning single-target sufficiency","pmid":"30683684"},{"claim":"STMN2 depletion alone may not recapitulate full axonal degeneration phenotype","pmid":"31247557"},{"claim":"Cryptic exon inclusion may be a secondary consequence rather than primary driver of neurodegeneration","pmid":"31846646"}],"verdict":"promising"}